Intravenous Glutamine Supplementation in Critically Ill Patients Receiving Enteral Feeding Reporter: 黃孜立 Instructor: 賴聖如 營養師 1 2 Abstract • Glutamine and Dipeptiven • Metabolism under stress • Paper – Metabolic Effects Of Enteral Versus Parenteral Alanyl-glutamine Dipeptide Administration In Critically Ill Patients Receiving Enteral Feeding: A Pilot Study – The Effect Of Intravenous Alanyl-glutamine Supplementation On Plasma Glutathione Levels In Intensive Care Unit Trauma Patients Receiving Enteral Nutrition: The Results Of A Randomized Controlled Trial – Effect Of Intravenous Glutamine Supplementation IN Trauma Patients Receiving Enteral Nutrition Study Protocol (GLINT Study): A Prospective, Blinded, Randomised, Placebo Controlled Clinical Trial • Conclusion 3 What is Glutamine (GLN) ? Endogenous 4 Glutamine Plasma Glutamine concentrations↑, improve: 1.Antioxidant capacity 2.Nitrogen balance ↑ 3.Immune function ↑ 4.Intestinal permeability ↑ 5.The incidence of hospital-acquired infection ↓ 5 Hypermetabolic response Major surgery Sepsis Fractures Trauma Hypermetabolic response Burns 6 Metabolism under stress REE Respiratory quotient Proteolysis Stress hypermetabolism ↑↑ 0.8-0.9 ↑↑ Hepatic protein synthesis Ureagenesis ↑↑ Gluconeogenesis ↑↑ Urinary nitrogen loss ↑↑ ↑↑ 7 Glutamine Therapy 8 Dipeptiven雙胜胺 Concentrated GLN solution containing the dipeptide alanyl-glutamine (Ala-Gln) 100 ml contains: 20 g N(2)-L-alanyl-L-glutamine =>13.46 g L-glutamine, 8.20 g L-alanine(= 3.87 g N) -Water for injection -Theoretical osmolarity: 921 mosmol/ l Indication In patients in catabolic and/ or hypermetabolic states Prescribing information Dosage per day:0.4 g Ala-Gln / kg BW (= 2.0 ml Dipeptiven®/ kg BW) Administration: For central venous infusion, as part of a PN regime 9 Aim of the three papers Intravenous glutamine 1.Antioxidant capacity 2.Nitrogen balance 3.Immune function 4.Intestinal permeability Control 5.The incidence of hospitalacquired infection 10 Metabolic Effects Of Enteral Versus Parenteral Alanylglutamine Dipeptide Administration In Critically Ill Patients Receiving Enteral Feeding: A Pilot Study Menghua Luo, Niloofar Bazargan, Daniel P. Griffith, Concepción Fernández-Estívariz, Lorraine M. Leader, Kirk A. Easley, Nicole M. Daignault, Li Hao, Jon B. Meddings, John R. Galloway, Jeffrey B. Blumberg, Dean P. Jones, and Thomas R. Ziegler Clinical Nutrition 27(2009),297–306 Metabolic effects of enteral versus parenteral alanyl-glutamine dipeptide administration in critically ill patients receiving enteral feeding: a pilot study 11 Objective To find the metabolic effects of intravenous (IV) alanyl-Gln dipeptide (AG) supplementation and enteral (EN) AG supplementation in adult critically ill patients requiring tube feeding Design double-blind, pilot clinical trial Setting surgical Intensive Care Unit (SICU) Patients Critically ill patients (N=44) in the ICU with indication for PN Excluded: active uncontrolled infection, hepatic dysfunction, renal dysfunction, active GI bleeding or gastric outlet obstruction, history of small intestinal or gastric resection 12 Metabolic effects of enteral versus parenteral alanyl-glutamine dipeptide administration in critically ill patients receiving enteral feeding: a pilot study Method Control:IV Gln-free amino acid (0.5g/kg/d) (n=15) Double-blind randonmization IV AG: IV Gln (0.5g/kg/d) (n=14) EN AG: IV placebo + EN Gln (0.5g/kg/d) (n=15) 3-day N blance Study day 1 Lab data 3 6 9 Iso-N, iso-caloric tube feeds Lab data 13 Metabolic effects of enteral versus parenteral alanyl-glutamine dipeptide administration in critically ill patients receiving enteral feeding: a pilot study Method Lab data: •Day1, 9: 1.plasma Gln 2.antioxidant indices 3.lymphocyte subsets 4.serum IGF-1 and IGF binding protein-3 5.intestinal permeability •Days 6 to 8: Nitrogen balance study 14 Metabolic effects of enteral versus parenteral alanyl-glutamine dipeptide administration in critically ill patients receiving enteral feeding: a pilot study Conclusion criteria Result (compared to control group) antioxidant capacity X No significant differences oxidative stress markers X No significant differences α-tocopherol EN AG group↑ T-lymphocyte subset number X No significant differences gut barrier function X No significant differences whole-body protein metabolism X No significant differences Plasama glutamine ↑ IV AG group: Significant increase 15 Plasama glutamine→ IV AG group: Significant increase 16 EN AG group : ↑ 17 IV AG group : ↑ 18 The Effect Of Intravenous Alanyl-glutamine Supplementation On Plasma Glutathione Levels In Intensive Care Unit Trauma Patients Receiving Enteral Nutrition: The Results Of A Randomized Controlled Trial Ahmet Eroglu, MD International Anesthesia Research Society 109(2009),502-505 The Effect of Intravenous Alanyl-Glutamine Supplementation on 19 Plasma Glutathione Levels in Intensive Care Unit Trauma Patients Receiving Enteral Nutrition: The Results of a Randomized Controlled Trial Objective IV alanyl-glutamine dipeptide supplementation↔plasma glutathione Design randomized, controlled study (double blind manner) Setting Intensive Care Unit (ICU) Patients 40 adult patients with severe trauma according to the Injury Severity Score(ISS) >20 Interventions 1. Group G received 0.5 g /kg/d of IV alanyl-glutamine dipeptide supplementation 2. Group C received a control solution without alanylglutamine for 7 days Parameter Blood samples: total glutathione, C reactive protein (CRP), prealbumin, and glucose before the initiation of supplementation and on the 3rd, 7th, and 10th days of feeding. 20 Conclusion IV alanyl-glutamine supplementation for 7 days → total plasma glutathione levels ↑ •No differences in : CRP, prealbumin, glucose 21 Effect Of Intravenous Glutamine Supplementation IN Trauma Patients Receiving Enteral Nutrition Study Protocol (GLINT Study): A Prospective, Blinded, Randomised, Placebo Controlled Clinical Trial Ruqaiya M Al Balushi,1 Jennifer D Paratz,1,2 Jeremy Cohen,1,2 Merrilyn Banks,3 Joel Dulhunty,1,2 Jason A Roberts,1,2 Jeffrey Lipman Al Balushi RM, Paratz JD, Cohen J, et al. BMJ Open 1(2011),1-7 22 Effect Of Intravenous Glutamine Supplementation IN Trauma Patients Receiving Enteral Nutrition Study Protocol (GLINT Study): A Prospective, Blinded, Randomised, Placebo Controlled Clinical Trial • Objective preservation of lean body mass IV alanyl-glutamine supplementation in multiple trauma patients receiving enteral nutrition infectious complications organ failure Design Prospective, Blinded, Randomised, Placebo Controlled Clinical Trial Setting Intensive Care Unit (ICU) Patients 88 critically ill patients with a diagnosis of multiple trauma requiring mechanical ventilation, patients requiring enteral feeding for >48 h, expected length of stay in the ICU >48 h Interventions 1. 2. parameter 1. 0.5 g/kg/day IV alanyl-glutamine IV placebo continuous infusion (24 h/day) & the same standard enteral nutrition protocol until discharge from the intensive care unit, death or a maximum duration of 3 weeks. 2. 3. 4. 5. Total sequential organ failure assessment score on the last day of treatment infectious complications during the ICU stay 60-day mortality length of stay in the intensive care unit fat-free mass and fat percentage 23 24 Strengths limitations Longer study period 1. Mortality 2. The long-term outcomes 3. Trauma patients with severe renal failure or hepatic impairment Objective 1 2 3 IV EN ↔ 1. 血糖 2. 抗氧化力 3. 免疫能力 4. 腸道保護 5. 住院天數、死亡率、 併發症 IV ↔ 1. 抗氧化力(plasma glutathione) 2. 血糖 3. 住院天數、死亡率、 併發症 IV ↔ 1.保留LBM能力 2.住院天數、死亡 率、併發症 3.ICU常規檢測數值 Comparison Design double-blind,RCT Setting ICU 25 Patients 44 40 88 Nutrition Regime 1. EN AG 2. IV AG 0.5 g /kg/d 3. control 1. IV :0.5 g /kg/d 2. control 1. IV :0.5 g/kg/day 2. Control 管灌多元配方 for 9 days Conclusion for 7 days IV:Plasama glutamine↑ IV:7.10day total plasma glutathione levels ↑ EN:α-tocopherol ↑ 最多3 weeks 26 Conclusion Parental glutamine Control 1.Antioxidant capacity 2.Nitrogen balance IV 3.Immune function 1.Plasma glutamine ↑ 4.Intestinal permeability 2.Plasma glutathione ↑ 5.The incidence of hospitalacquired infection 27 THANK YOU FOR YOUR ATTENTION